ReviewJournal of neural transmission (Vienna, Austria : 1996)2018
Let's make microglia great again in neurodegenerative disorders.
Review in Journal of neural transmission (Vienna, Austria : 1996), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Plasma MCP-1 and changes on cognitive function in community-dwelling older adults.Alzheimer's research & therapy · 2022Trial
- Food for thought: probiotic modulation of microglial activity in Parkinson's disease.Frontiers in molecular neuroscience · 2025Review
- Towards early detection of neurodegenerative diseases: A gut feeling.Frontiers in cell and developmental biology · 2023Review
- Innate immunity stimulation via CpG oligodeoxynucleotides ameliorates Alzheimer's disease pathology in aged squirrel monkeys.Brain : a journal of neurology · 2021Article
- Microglia Activation in Retinal Ischemia Triggers Cytokine and Toll-Like Receptor Response.Journal of molecular neuroscience : MN · 2021Article
- Megalencephalic Leukoencephalopathy with Subcortical Cysts Protein-1 (MLC1) Counteracts Astrocyte Activation in Response to Inflammatory Signals.Molecular neurobiology · 2019Article
- Saffron: A Multitask Neuroprotective Agent for Retinal Degenerative Diseases.Antioxidants (Basel, Switzerland) · 2019Article
- Neuroinflammation in neurodegeneration: role in pathophysiology, therapeutic opportunities and clinical perspectives.Journal of neural transmission (Vienna, Austria : 1996) · 2018Article
- Role of Microglia TLRs in Neurodegeneration.Frontiers in cellular neuroscience · 2018Article
- Emerging Biosensing Technologies for Neuroinflammatory and Neurodegenerative Disease Diagnostics.Frontiers in molecular neuroscience · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
All of the common neurodegenerative disorders-Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and prion diseases-are characterized by accumulation of misfolded proteins that trigger activation of microglia; brain-resident mononuclear phagocytes. This chronic form of neuroinflammation is earmarked by increased release of myriad cytokines and chemokines in patient brains and biofluids. Microglial phagocytosis is compromised early in the disease process, obfuscating clearance of abnormal proteins. This review identifies immune pathologies shared by the major neurodegenerative disorders. The overarching concept is that aberrant innate immune pathways can be targeted for return to homeostasis in hopes of coaxing microglia into clearing neurotoxic misfolded proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.